Skip to main content
Caplight Logo









Drusolv Therapeutics

Drusolv Therapeutics

Private
Philadelphia, PennsylvaniaHealthcare & Life Scienceshttps://drusolv.com/

Last Round

Series A

May 30, 2023

Total Funding Raised

$2.5M

Company Overview

Drusolv Therapeutics is a drug discovery company that is developing a high-dose oral statin for early intervention in age-related macular degeneration (AMD).

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

age-related macular degenerationAMDbiopharmaceuticaldrug repurposingatorvastatinophthalmologyclinical-stage biotechdrug developmentvision loss preventiontherapeutic candidateclinical trialsbiotech startup

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Drusolv Therapeutics Comparables

Compare Drusolv Therapeutics with similar companies based on industry and business-model similarity.

Drusolv Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
InflammX Therapeutics
88%
Allegro Ophthalmics
80%
Morningside
76%

Drusolv Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AMay 30, 2023
SeedApr 12, 2022
GrantMar 31, 2022

Drusolv Therapeutics Investors

Notable investors and investment history

Drusolv Therapeutics investors
InvestorRounds
BrightFocus FoundationSeed, Grant, Series A
Texas Halo FundSeed, Series A

Drusolv Therapeutics Filings

Explore SEC and related filing metadata, where available.

Drusolv Therapeutics filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Drusolv Therapeutics's valuation, stock price, and market status.

Is Drusolv Therapeutics a public or private company?

Drusolv Therapeutics is a private company.

What is the current stock price of Drusolv Therapeutics?

Drusolv Therapeutics is a private company with no public stock price. No recent secondary market data is available.

How much is Drusolv Therapeutics worth (valuation)?

Valuation information for Drusolv Therapeutics is not publicly available.

Can I buy Drusolv Therapeutics stock?

Drusolv Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Drusolv Therapeutics's last funding round?

Drusolv Therapeutics's most recent funding round was Series A on May 30, 2023.

Who are the main investors in Drusolv Therapeutics?

Key investors in Drusolv Therapeutics include BrightFocus Foundation, Texas Halo Fund.

Will Drusolv Therapeutics IPO soon?

No public IPO plans have been announced for Drusolv Therapeutics.

How can I track Drusolv Therapeutics secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Drusolv Therapeutics's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersPhiladelphia, Pennsylvania
Employee Range1
Year Founded2017
Last FundingMay 30, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?